CEO Lena Heffler: “I’m pleased to see this trend of existing customers returning to purchase a second instrument from ISAB. It speaks volumes about the quality of data, range of capabilities and important competitive edge PreciseInhale gives them”. ISAB’s PreciseInhale aerosol generator generates accurate in vivo and ex vivo data, from nebulized solutions as well as commercial dry powder inhalers. The new purchase includes ISAB’s new integrated nebulizer feature, which the company launched in February 2019 (http://www.preciseinhale.com/lab-blog/precision-control-whether-wet-or-dry-new-nebulizer-feature-launched/). CEO Lena Heffler: "This sale is a clear indication of the scientific and strategic value PreciseInhale gives companies—enabling them to generate more accurate data, minimize risk and accelerate research. We’re delighted with our customers’ confidence in our technology’s capabilities.”